Can xolair be used to treat severe peanut allergies?

Is Xolair Approved for Severe Peanut Allergies?

Xolair (omalizumab) is FDA-approved to reduce allergic reactions, including anaphylaxis, after accidental peanut exposure in adults and children aged 1 year and older with IgE-mediated peanut allergy confirmed by testing.[1] It is specifically indicated for patients with severe peanut allergies who have a history of reactions and are at risk from unintentional ingestion.

How Does Xolair Work for Peanut Allergies?

Xolair is an anti-IgE monoclonal antibody that binds free IgE, preventing it from attaching to mast cells and basophils. This lowers sensitivity to peanuts, allowing patients to tolerate higher accidental doses (up to 600 mg peanut protein in trials) without severe symptoms.[1][2] It does not cure the allergy or enable safe peanut consumption.

Who Qualifies for Xolair Treatment?

Eligibility requires:
- Positive skin prick or blood test for peanut-specific IgE.
- History of severe reaction (e.g., anaphylaxis).
- Baseline peanut sensitivity shown via oral food challenge.
It is used alongside strict peanut avoidance and epinephrine auto-injectors, not as a replacement.[1]

What Do Clinical Trials Show?

In the phase 3 OUtMATCH trial, 29% of Xolair-treated patients tolerated a 600 mg peanut challenge (about three peanuts) after 16-20 weeks, compared to 7% on placebo. Reactions were milder in treated patients.[2] A pediatric substudy confirmed similar results in children aged 1-17.[3]

When Is It Not Recommended?

Xolair is not for mild allergies, non-IgE reactions, or as first-line therapy. It lacks approval for other food allergies like tree nuts or milk, though trials explore broader use.[1] Not suitable if patients can already tolerate small amounts without reaction.

Common Side Effects and Risks

Injection-site reactions occur in 40-60% of patients. Anaphylaxis risk exists (0.1% per dose), requiring monitoring for 30 minutes post-injection. Long-term safety data covers up to 2 years.[1][2]

Dosing and Administration

Dosed every 2-4 weeks subcutaneously based on weight and IgE levels (75-600 mg). Pre-treatment blood tests determine exact dose.[1]

Cost and Access

List price is about $3,000-$5,000 per monthly dose, often covered by insurance for approved uses. Patient assistance programs exist via Genentech.[4]

Alternatives to Xolair

• Oral Immunotherapy (OIT): Palforzia (peanut desensitization) for ages 4-17; daily dosing builds tolerance but carries daily reaction risk.[5]
  
• Epicutaneous immunotherapy (EPIT): Viaskin Peanut (patch) in late-stage trials.
  
• Sublingual immunotherapy: Off-label, less standardized.
  Xolair offers faster onset (16 weeks) vs. OIT's gradual buildup.
  
  [1]: FDA Label for Xolair (omalizumab)
  [2]: NEJM: OUtMATCH Trial Results
  [3]: NIAID Summary on Peanut Allergy Treatments
  [4]: Genentech Xolair Access
  [5]: FDA Label for Palforzia